v3.25.1
Segment Reporting
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting Disclosure Segment Data
The Company has a single operating and reportable segment. The Company derives revenues from the manufacture and sale of our medical products which are used in infusion therapy, vascular access, and vital care applications. Our product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, IV catheters, sharps safety products, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Our product lines, as disclosed in Note 5: Revenue, were determined to be a single operating segment as discrete financial information by product-line is limited to revenue and standard cost. Other cost of sale expenses, which include above-site manufacturing costs, manufacturing variances and supply chain costs including freight and warehousing are not allocated to individual product lines. Similarly, quality, regulatory and other operating expenses are only provided to our chief operating decision maker ("CODM") at the consolidated level.

For information on disaggregation of revenues by product-line and geography, see Note 5: Revenue.

Our chief executive officer is our CODM. Our CODM uses net profit (loss) to manage our business activities on a consolidated basis and to evaluate and assess the performance of the Company when determining how to allocate capital resources. Our segment performance is monitored and resource allocation is determined during the consolidated annual budget/forecast processes. The measure of segment assets is reported on the consolidated balance sheets as total assets. Expenditures for additions to long-lived assets were $16.9 million and $18.9 million for the three months ended March 31, 2025 and 2024, respectively.

The following table presents information about our segment revenue, segment profit or loss, and significant segment expenses (in thousands):

Three months ended
March 31,
20252024
REVENUES$604,702 $566,655 
Less:
Standard COGS(1)
$293,408 $283,001 
Quality remediation/recall(2)
$9,980 $7,498 
Other COGS(3)
$91,205 $90,912 
Selling, general and administrative$157,233 $157,657 
Research and development$23,291 $21,842 
Restructuring and integration$16,697 $16,105 
Other segment items(4)
$(1,469)$(9)
Interest expense$25,263 $26,417 
Income tax provision$4,570 $2,703 
Consolidated net loss$(15,476)$(39,471)
_______________
(1) Represents the average annual budgeted cost of producing each good sold in the period.
(2) Represents significant labor and material costs to replace or repair a product outside the scope of standard warranty and compliance costs related to quality systems and manufacturing operations.
(3) Includes costs related to capitalized manufacturing variances to standard COGS, supply chain and logistics costs including freight, inventory management and reserves, hardware service, quality and regulatory, and operations and supply chain management costs.
(4) Includes changes in fair value of contingent earn-out, interest income, gain/loss on disposition of assets, gain/loss on foreign exchange, other miscellaneous income/expense and equity in the income of equity method investees.

For information on depreciation expense, see Note 14: Property, Plant, & Equipment. For information on amortization expense, see Note 15: Goodwill and Intangible Assets, Net.

Significant Customers
 
We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to end customers. The manufacturers and distributors, in turn, sell our products to healthcare providers. For the three months ended March 31, 2025 and 2024, we had net sales of 17%, and 17%, respectively, of consolidated worldwide net sales to a single distributor.

Geographic Information

The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):
 As of
 March 31, 2025December 31, 2024
Costa Rica157,576 156,149 
Mexico112,378 111,043 
Other LATAM59,660 55,451 
Canada1,493 5,284 
Italy31,093 29,124 
Spain18,119 17,141 
Czech Republic12,576 11,909 
Other Europe10,767 11,445 
APAC27,365 27,550 
Total Foreign $431,027 $425,096 
United States*618,863 610,547 
Worldwide Total$1,049,890 $1,035,643 
________________________________
*As of March 31, 2025 and December 31, 2024, we presented within the assets held for sale line item in our consolidated balance sheet, the gross long-lived assets that were part of a disposal group that met the criteria as held for sale during the fourth quarter of 2024 (See Note 4: Assets Held For Sale).